The molecular pathology of ovarian serous borderline tumors

Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum

(2015) David M Gershenson et al.   BRITISH JOURNAL OF CANCER

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer

(2015) Rachel N. Grisham et al.   JOURNAL OF CLINICAL ONCOLOGY

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Meta-Analysis on the Impact of Platinum-Based Adjuvant Treatment on the Outcome of Borderline Ovarian Tumors With Invasive Implants

(2015) I. Vasconcelos et al.   ONCOLOGIST

BRAF Mutation Is Associated With a Specific Cell Type With Features Suggestive of Senescence in Ovarian Serous Borderline (Atypical Proliferative) Tumors

(2014) Felix Zeppernick et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Monoclonal Origin of Peritoneal Implants and Lymph Node Deposits in Serous Borderline Ovarian Tumors (s-BOT) With High Intratumoral Homogeneity

(2014) Lars-Christian Horn et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas

(2013) Dinka Sundov et al.   Diagnostic Pathology

Whole exome sequence analysis of serous borderline tumors of the ovary

(2013) Jeff Boyd et al.   GYNECOLOGIC ONCOLOGY

KRAS(but notBRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma

(2013) Yvonne T Tsang et al.   JOURNAL OF PATHOLOGY

Mutational analysis ofBRAFandKRASin ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants

(2013) Laura Ardighieri et al.   JOURNAL OF PATHOLOGY

Ovarian Serous Tumors of Low Malignant Potential With Nodal Low-grade Serous Carcinoma

(2012) Bojana Djordjevic et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer

(2012) Rachel N. Grisham et al.   CANCER

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum

(2012) David M. Gershenson et al.   GYNECOLOGIC ONCOLOGY

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

(2012) John Farley et al.   LANCET ONCOLOGY

Borderline Tumors of the Ovary: Clinical Course and Prognostic Factors

(2012) Nina Ewald-Riegler et al.   ONKOLOGIE

BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas

(2010) Kwong-Kwok Wong et al.   AMERICAN JOURNAL OF PATHOLOGY

v-Raf Murine Sarcoma Viral Oncogene Mutation Status in Serous Borderline Ovarian Tumors and the Effect on Clinical Behavior

(2010) Marjolijn B. Verbruggen et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Loss of p16INK4A Expression in Low-grade Ovarian Serous Carcinomas

(2010) Peter W. Schlosshauer et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors

(2010) Ildikó Vereczkey et al.   PATHOLOGY & ONCOLOGY RESEARCH

Lymph Node Involvement in Ovarian Serous Tumors of Low Malignant Potential: A Clinicopathologic Study of Thirty-six Cases

(2009) Bojana Djordjevic et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors

(2008) M. S. Anglesio et al.   MOLECULAR CANCER RESEARCH